ArticleCVIR endovascular2026
Percutaneous intrabiliary injection of gelatin sponge slurry for the management of acute hemobilia during biliary interventions: an alternative salvage technique.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate percutaneous intrabiliary injection of gelatin sponge (Gelfoam) slurry as a preliminary salvage technique for acute hemobilia during biliary interventions when angiographic embolization is unavailable. MATERIAL AND
methodsWe retrospectively reviewed eight patients with significant hemobilia during percutaneous biliary procedures between September 2024 and December 2025. Notably, seven patients (87.5%) had pre-existing clinical cholangitis that was controlled with therapeutic antibiotics prior to the bleeding event. Gelfoam slurry was injected directly into the biliary tree or tract to achieve hemostasis via internal compression and the promotion of localized thrombosis, while maintaining post-procedural catheter drainage and continued antibiotic coverage.
resultsImmediate technical hemostasis was achieved in all cases (100%). One instance of recurrent bleeding at 10 days was successfully managed with a repeat injection. Post-procedural infectious episodes (fever, leukocytosis) were observed in two patients (25%), requiring an upgrade in targeted antibiotic therapy. The pre-existing infectious baseline in the majority of the cohort complicates the distinction between recurrent cholangitis and de novo foreign-body-related infection.
conclusionPreliminary experience suggests that intrabiliary Gelfoam slurry may represent a potential bridging or salvage maneuver for acute hemobilia in resource-constrained scenarios. However, because it relies on internal compression rather than definitive vascular repair, and carries potential risks of infectious exacerbation, it should be applied cautiously with strict follow-up and does not replace definitive transcatheter arterial embolization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.